ROUNDUP: Evotec continues to grow and confirms forecasts – shares under pressure

Thursday, 11/11/2021 2:33 PM from


| Views: 54

Scientists at work with microscope and pipette (symbolic image). © Catalin Rusnac / iStock / Getty Images Plus / Getty Images

HAMBURG (dpa-AFX) – The drug researcher Evotec (Evotec share) has grown strongly so far this year. The Hamburg-based company benefited from significantly increased milestone payments and higher contributions from their US subsidiary, as the company announced on Thursday for the publication of the final figures. Since the key data presented a few weeks ago, it was clear that Evotec earned less operationally: A tribute to the start-up of a production facility. CEO Werner Lanthaler sees the MDax -Group remains on the path to its growth targets for this year and its medium-term projections up to 2025.

On the stock exchange, Evotec shares temporarily slipped by almost 5 percent on Thursday, but then managed to recover a little. Most recently there was a minus of around one and a half percent on the course slip. Investors currently seem to be looking for direction. After the paper had soared to a high since 2000 in mid-September, it is tending to decline despite the interim recovery.


Further down?

Short-term position in Evotec

Ask: 10,22

Leverage: 4.37

with moderate leverage

Morgan Stanley

The base prospectus as well as the final terms and the key information sheets are available here: MA8 OUT,. Also note the further notes to this advertisement. The issuer is entitled to terminate securities with an open-end term.


Subscribe to more news about Novavax shares free of charge

ARIVA.DE publishes analyzes, columns and news from various sources in this section. ARIVA.DE AG is not responsible for content that is recognizably posted by third parties in the “News” area of ​​this website and does not adopt it as its own. This content can be identified in particular by a corresponding “from” label below the article heading and / or by the link “To read the full article, please click here.”; The named third party is solely responsible for this content.

Other users were also interested in this article:

Leave A Comment